Effect of impaired glucose tolerance on cardiac dysfunction in a rat model of prediabetes

Chinese Medical Journal

Volumn 124, Issue 5, 2011, Pages 734-739

  Liang, Jia Liang ^a,b   Feng, Zhi Kuan ^a   Liu, Xiao Ying ^a   Lin, Qiu Xiong ^a   Fu, Yong Heng ^a   Shan, Zhi Xin ^a   Zhu, Jie Ning ^a   Lin, Shu guang ^a   Yu, Xi Yong ^a  

^a GUANGDONG PROVINCIAL PEOPLE'S HOSPITAL   (China)

^b SOUTHERN MEDICAL UNIVERSITY   (China)

Author keywords

Apoptosis; Cardiac dysfunction; Impaired glucose tolerance; Metabolism; Prediabetes

Indexed keywords

CASPASE 3; G PROTEIN COUPLED RECEPTOR KINASE 2; GLUCOSE; GLYCOGEN; MACROPHAGE MIGRATION INHIBITION FACTOR; STREPTOZOCIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; ECHOCARDIOGRAPHY; ENZYME ACTIVATION; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; GLYCOGEN STORAGE DISEASE; HEART DISEASE; HEART EJECTION FRACTION; HEART MUSCLE CELL; IMPAIRED GLUCOSE TOLERANCE; NICK END LABELING; NONHUMAN; PATHOGENESIS; PERIODIC ACID SCHIFF STAIN; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; RAT; STREPTOZOCIN DIABETES; WESTERN BLOTTING;

ANIMALS; APOPTOSIS; BLOTTING, WESTERN; DISEASE MODELS, ANIMAL; ECHOCARDIOGRAPHY; G-PROTEIN-COUPLED RECEPTOR KINASE 2; GLUCOSE INTOLERANCE; GLUCOSE TOLERANCE TEST; IN SITU NICK-END LABELING; INTRAMOLECULAR OXIDOREDUCTASES; MACROPHAGE MIGRATION-INHIBITORY FACTORS; MYOCARDIUM; MYOCYTES, CARDIAC; RATS; STREPTOZOCIN;

EID: 79952527316     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0366-6999.2011.05.019     Document Type: Article

References (32)

1. Abdul-Ghani MA, Defronzo RA. Pathophysiology of prediabetes. Curr Diab Rep 2009; 9: 193-199.
2. Bacha F, Gungor N, Lee S, Arslanian SA. In vivo insulin sensitivity and secretion in obese youth: what are the differences between normal glucose tolerance, impaired glucose tolerance, and type 2 diabetes? Diabetes Care 2009; 32: 100-105.
3. Roman G, Hancu N. Early insulin treatment to prevent cardiovascular disease in prediabetes and overt diabetes. Horm Metab Res 2009; 41: 116-122.
4. Broderick TL, Hutchison AK. Cardiac dysfunction in the euglycemic diabetic-prone BB Wor rat. Metabolism 2004; 53: 1391-1394.
5. Mizushige K, Yao L, Noma T, Kiyomoto H, Yu Y, Hosomi N, et al. Alteration in left ventricular diastolic filling and accumulation of myocardial collagen at insulin-resistant prediabetic stage of a type II diabetic rat model. Circulation 2000; 101: 899-907.
6. O'Keefe JH, Bell DS. Postprandial hyperglycemia/hyperlipidemia (postprandial dysmetabolism) is a cardiovascular risk factor. Am J Cardiol 2007; 100: 899-904.
7. Cai L, Li W, Wang G, Guo L, Jiang Y, Kang YJ. Hyperglycemia-induced apoptosis in mouse myocardium: mitochondrial cytochrome c-mediated caspase-3 activation pathway. Diabetes 2002; 51: 1938-1948.
8. Verschuren L, Kooistra T, Bernhagen J, Voshol PJ, Ouwens DM, Van EM, et al. Mif deficiency reduces chronic inflammation in white adipose tissue and impairs the development of insulin resistance, glucose intolerance, and associated atherosclerotic disease. Circ Res 2009; 105: 99-107.
9. Stosic-Grujicic S, Stojanovic I, Maksimovic-Ivanic D, Momcilovic M, Popadic D, Harhaji L, et al. Macrophage migration inhibitory factor (MIF) is necessary forprogression of autoimmune diabetes mellitus. J Cell Physiol 2008; 215: 665-675.
10. Hoi AY, Iskander MN, Morand EF. Macrophage migration inhibitory factor: a therapeutic target across inflammatory diseases. Inflamm Allergy Drug Targets 2007; 6: 183-190.
11. Kudrin A, Ray D. Cunning factor: macrophage migration inhibitory factor as a redox-regulated target. Immunol Cell Biol 2008; 86: 232-238.
12. Buvall L, Bollano E, Chen J, Shultze W, Fu M. Phenotype of early cardiomyopathic changes induced by activeimmunization of rats with a synthetic peptide corresponding to the second extracellular loop of the human beta-adrenergic receptor. Clin Exp Immunol 2006; 143: 209-215.
13. Abebe W, Mozaffari MS. Vascular reactivity changes in glucose-intolerant rat. J Cardiovasc Pharmacol 2007; 50: 590-597.
14. Striffler JS, Nadler JL. Lisofylline, a novel anti-inflammatory agent, enhances glucose-stimulated insulin secretion in vivo and in vitro: studies in prediabetic and normal rats. Metabolism 2004; 53: 290-296.
15. Coope GJ, Atkinson AM, Allott C, Mckerrecher D, Johnstone C, Pike KG, et al. Predictive blood glucose lowering efficacy by glucokinase activators in high fat fed female Zucker rats. Br J Pharmacol 2006; 149: 328-335.
16. Zhang YQ, Zhang YN, Cui C, Fan Y, Chang ML, Yu WG, et al. The role of oral glucose tolerance test in screening for diabetes mellitus in the elderly of Harbin, China. Chin Med J 2005; 118: 418-420.
17. An D, Rodrigues B. Role of changes in cardiac metabolism in development of diabetic cardiomyopathy. Am J Physiol Heart Circ Physiol 2006; 291: H1489-H1506.
18. Park TS, Hu Y, Noh HL, Drosatos K, Okajima K, Buchanan J, et al. Ceramide is a cardiotoxin in lipotoxic cardiomyopathy. J Lipid Res 2008; 49: 2101-2112.
19. Mandrup-Poulsen T. Apoptotic signal transduction pathways in diabetes. Biochem Pharmacol 2003; 66: 1433-1440.
20. Li Y, Li Y, Feng Q, Arnold M, Peng T. Calpain activation contributes to hyperglycaemia-induced apoptosis in cardiomyocytes. Cardiovasc Res 2009; 84: 100-110.
21. Zheng TS, Schlosser SF, Dao T, Hingorani R, Crispe IN, Boyer JL, et al. Caspase-3 controls both cytoplasmic and nuclear events associated with fas-mediated apoptosis in vivo. Proc Natl Acad Sci USA 1998; 95: 13618-13623.
22. Penela P, Murga C, Ribas C, Tutor AS, Peregrin S, Jr Mayor F. Mechanisms of regulation of g protein-coupled receptor kinases (grks) and cardiovascular disease. Cardiovasc Res 2006; 69: 46-56.
23. Garner LB, Willis MS, Carlson DL, Dimaio JM, White MD, White DJ, et al. Macrophage migration inhibitory factor is a cardiac-derived myocardial depressant factor. Am J Physiol Heart Circ Physiol 2003; 285: H2500-H2509.
24. Lin SG, Yu XY, Chen YX, Huang XR, Metz C, Bucala R, et al. De novo expression of macrophage migration inhibitory factor in atherogenesis in rabbits. Circ Res 2000; 87: 1202-1208.
25. Wang L, Zis O, Ma G, Shan Z, Zhang X, Wang S, et al. Upregulation of macrophage migration inhibitory factor gene expression in stroke. Stroke 2009; 40: 973-976.
26. Takahashi M, Nishihira J, Shimpo M, Mizue Y, Ueno S, Mano H, et al. Macrophage migration inhibitory factor as a redox-sensitive cytokine in cardiac myocytes. Cardiovasc Res 2001; 52: 438-445.
27. Yu XY, Song YH, Geng YJ, Lin QX, Shan ZX, Lin SG, et al. Glucose induces apoptosis of cardiomyocytes via microRNA-1 and IGF-1. Biochem Biophys Res Commun 2008; 376: 548-552.
28. Kumar S, Sitasawad SL. N-acetylcysteine prevents glucose/glucose oxidase-induced oxidative stress, mitochondrial damage and apoptosis in h9c2 cells. Life Sci 2009; 84: 328-336.
29. Dhanantwari P, Nadaraj S, Kenessey A, Chowdhury D, Al-Abed Y, Miller EJ, et al. Macrophage migration inhibitory factor induces cardiomyocyte apoptosis. Biochem Biophys Res Commun 2008; 371: 298-303.
30. Shi X, Leng L, Wang T, Wang W, Du X, Li J, et al. CD44 is the signaling component of the macrophage migration inhibitory factor-CD74 receptor complex. Immunity 2006; 25: 595-606.
31. Leng L, Metz CN, Fang Y, Xu J, Donnelly S, Baugh J, et al. MIF signal transduction initiated by binding to CD74. J Exp Med 2003; 197: 1467-1476.
32. Fiordaliso F, Leri A, Cesselli D, Limana F, Safai B, Nadal-Ginard B, et al. Hyperglycemia activates p53 and p53-regulated genes leading to myocyte cell death. Diabetes 2001; 50: 2363-2375.